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Background: There is an 80% prevalence of two or more psychiatric symptoms in psychogeriatric patients. Multiple
psychiatric symptoms (MPS) have many negative effects on quality of life of the patient as well as on caregiver
burden and competence. Irrespective of the effectiveness of an intervention programme, it is important to take into
account its economic aspects.
Methods: The economic evaluation was performed alongside a single open RCT and conducted between 2001
and 2006. The patients who met the selection criteria were asked to participate in the RCT. After the patient or his
caregiver signed a written informed consent form, he was then randomly assigned to either IRR or UC.
The costs and effects of IRR were compared to those of UC. We assessed the cost-utility of IRR as well as the cost-
effectiveness of both conditions. Primary outcome variable: severity of MPS (NPI) of patients; secondary outcome
variables: general caregiver burden (CB) and caregiver competence (CCL), quality of life (EQ5D) of the patient, and
total medical costs per patient (TiC-P). Cost-utility was evaluated on the basis of differences in total medical costs).
Cost-effectiveness was evaluated by comparing differences of total medical costs and effects on NPI, CB and CCL
(Incremental Cost-Effectiveness Ratio: ICER). CEAC-analyses were performed for QALY and NPI-severity. All significant
testing was fixed at p<0.05 (two-tailed). The data were analyzed according to the intention-to-treat (ITT)-principle. A
complete cases approach (CC) was used.
Results: IRR turned out to be non-significantly, 10.5% more expensive than UC (€ 36 per day). The number of
QALYs was 0.01 higher (non-significant) in IRR, resulting in € 276,290 per QALY. According to the ICER-method, IRR
was significantly more cost-effective on NPI-sum-severity of the patient (up to 34%), CB and CCL (up to 50%), with
ICERs varying from € 130 to € 540 per additional point of improvement.
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Conclusions: No significant differences were found on QALYs. In IRR patients improved significantly more on
severity of MPS, and caregivers on general burden and competence, with incremental costs varying from € 130 to
€ 540 per additional point of improvement. The surplus costs of IRR are considered acceptable, taking into account
the high societal costs of suffering from MPS of psychogeriatric patients and the high burden of caregivers. The
large discrepancy in economic evaluation between QALYs (based on EQ5D) and ICERs (based on clinically relevant
outcomes) demands further research on the validity of EQ5D in psychogeriatric cost-utility studies. (Trial registration
nr.: ISRCTN 38916563; December 2004).
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In psychogeriatric patients who suffer from cognitive im-
pairment or dementia, there is an 80% prevalence of two
or more psychiatric symptoms, e.g. depression, anxiety,
paranoia, aggression [1,2]. Multiple psychiatric symptoms
(MPS) have many related negative effects on the quality of
life of the patients as well as on caregiver burden and com-
petence [1,3,4]. Psychotropic drugs, e.g. (a) typical antipsy-
chotics, are widely used to treat the MPS in usual nursing
home care, despite their limited effects and potentially
harmful side-effects [5,6]. Reports in the literature indicate
that psychotherapeutic treatment may be effective for indi-
vidual psychiatric symptoms [7]. However, psychothera-
peutic interventions that focus on MPS are complex, due
to the multiple nature of MPS in combination with cogni-
tive disorders, somatic co-morbidity, and social problems.
Furthermore, our literature search did not reveal any large-
scale, comprehensive randomized controlled (RCT) studies
on integrative psychotherapeutic programmes in nursing
homes [8,9]. For these reasons, we developed a unique
integrative psychotherapeutic nursing home programme:
integrative reactivation and rehabilitation (IRR) [10]. The
IRR-programme was aimed at psychogeriatric patients who
were at high risk for admission to a nursing home. Limits
on health-care resources mandate that resource-allocation
decisions are guided by considerations of costs in relation
to expected benefits. In cost-effectiveness analysis, the ratio
of net health-care costs to net health benefits provides an
index by which priorities may be set. Quality-of-life con-
cerns are commonly incorporated in the calculation of
health benefits as adjustments to life expectancy [11]. The
incremental cost-effectiveness ratio (ICER) is the ratio of
the estimated difference between the costs of two interven-
tions and the estimated difference between the outcomes
of these two interventions. Cost-effectiveness studies are
mainly used to facilitate informed decision making about
interventions that are both more costly and more effective
than their comparator. The performed RCT was designed
to test the (cost-effectiveness) of IRR on MPS of psycho-
geriatric patients as well as on burden and competence ofthe caregiver. The primary analyses concerned the mean
differences between IRR and the usual multidisciplinary
nursing home care (UC) on continuous data of the out-
come variables. The results of this analysis are published
elsewhere [12]. IRR had a significant and moderate to large
surplus effect (up to 34%) on reducing the MPS of psycho-
geriatric patients. In fact, at six-month follow-up there was
a total reduction up to 46% in number and 61% in severity.
Furthermore, at the end of the treatment IRR had a large
surplus effect (up to 36%) on reducing caregiver burden.
During the follow-up the surplus effect even increased
up to 50%, while UC showed almost no effect. Irrespective
of their effectiveness, the economic aspect of treatment
programmes, i.e. an economic evaluation from a societal
perspective, is also important [13]. The costs and effects
of IRR were compared to those of UC. We assessed the
cost-utility of IRR as well as the cost-effectiveness of both
conditions on three outcome variables.Methods
Patients
In the urban region of Nieuwe Waterweg Noord (NWN),
near Rotterdam in the Netherlands, the patients were re-
ferred from an (ambulant) mental health service (5.4%), a
general hospital (13.8%), a memory clinic (6%) and by gen-
eral practitioners or primary healthcare services (75.1%).
Before inclusion in the randomized controlled trial, all pa-
tients underwent a comprehensive assessment. The inclu-
sion criteria were: 1) Diagnostic and Statistical Manual
(DSM IV) classification of dementia, amnestic disorders
or other cognitive disorders; 2) age: ≥65 years; 3) psychi-
atric symptoms: Neuropsychiatric Inventory (NPI) 3 or
more symptoms; 4) cognitive functioning: Mini Mental
Status Examination (MMSE) ≥18 and ≤27 as well as
Barthel Index (BI) ≥5 and ≤19, and 5) informed consent.
The exclusion criteria were: 1) delirium; 2) life-threatening
somatic co-morbidity; 3) active compulsory admission re-
gime (according to psychiatric legislation), and 4) insuffi-
cient command of the Dutch language.
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The economic evaluation was performed alongside an
open Randomised Controlled Trial (RCT), conducted
between 2001 and 2006. Included patients were ran-
domly and blindly assigned to either IRR or UC, using a
randomisation algorithm. In the first half of the study
the assignment ratio was 1 (IRR):2 (UC). However, due
to the limited number of eligible patients, time restric-
tions and financial limitations, this was reversed to 2
(IRR):1 (UC) in the second half of the study. We ultim-
ately included 168 patients (81 IRR and 87 UC).
‘Multiple psychiatric symptoms of the patient’ was the
primary outcome variable, and ‘Burden’ and ‘Compe-
tence’ of the caregiver were secondary outcome vari-
ables. For the economic evaluation we collected the data
of direct medical costs of the patient. The outcome vari-
ables were assessed at T1 (within two weeks after intake)
and at T3 (follow-up; six months after the conclusion of
the three-month intervention). Measurements of the
costs were conducted every 8 weeks over the previous
four weeks. The final measurement took place at
40 weeks. Data were collected by trained assessors who
were not members of the Intervention team. Assessors
were not blind to the intervention. This study was ap-
proved by the Medical Ethics Review Committee
(METC) of the Erasmus University Medical Centre.
Intervention
The duration of IRR programme was 13 weeks, with
clinical admission to a separate 15-bed specialized unit
in a psychiatric-skilled nursing home. IRR is meant as a
short-stay reactivation and rehabilitation programme in
addition to the usual multidisciplinary nursing home
care, including psychotropic drug treatment. IRR
consisted of both integrative psychotherapeutic interven-
tions to treat multiple psychiatric symptoms of the pa-
tient, and family therapy for the caregiver. Furthermore,
both cognitive and somatic functioning were optimized.
The patients followed the IRR program in three phases:
1. diagnostics, 2. treatment, and 3. discharge (Figure 1).
The multidisciplinary IRR team consisted of a nursing
team, a psychogeriatrician, a clinical psychologist, a so-
cial worker, a music therapist, a psychomotor therapist
and a creative therapist, a physiotherapist, an occupa-
tional therapist, a speech therapist, a dietician and a wel-
fare worker [12]. In the diagnostic phase (phase 1) a
personal package of interventions was put together for
each patient and caregiver, based on selected specific
functional problems on six dimensions: ‘Emotion’ (e.g.
depression, anxiety, aggression), ‘Personality’ (e.g. charac-
teristics of narcissism, borderline personality disorder,
dependency), ‘Life events’ (e.g. traumatic experiences
such as war, incest, death of a spouse/child), ‘Social
functioning’ (e.g. relationship problems with spouse/children, loss of pleasant social activities), ‘Cognitive
functioning’ (e.g. problems with memory, self-care),
and ‘Somatic functional disorders’ (e.g. impaired mobil-
ity, falls, polypharmacy, nutritional deficiency and inter-
current diseases) [10]. In the treatment phase (phase 2)
and the discharge phase (phase 3), the following psy-
chotherapeutic interventions - which were based on a
problem-solving theoretical framework and recorded in
guidelines for each discipline - were applied: 1) diagnostic
assessment, 2) counselling, 3) life-review, 4) interpersonal
therapy, 5) cognitive-behavioural therapy, 6) behavioural
therapy, 7) support in accepting behaviour and minim-
izing negative effects, 8) regression approach, tempor-
arily accepting regression behaviour, 9) rehabilitation,
10) support from social worker on discharge, 11)
psycho-education, and 12) family therapy [10,12]. The
percentages in Figure 1 correspond to the percentages
of patients who participated in the specific intervention
during the IRR phases. A patient could participate in
different interventions prescribed for the specific func-
tional problems.
Interventions were provided mainly in a group setting,
but also individually when necessary. On average pa-
tients received treatment for five functional psychiatric
problems, provided by four disciplines; sometimes a dis-
cipline used more than one type of intervention. The
availability of a wide range of interventions made it
possible to provide a highly individualized package of
interventions. After multidisciplinary consultation, the
psychogeriatrician - a nursing home physician with ex-
perience in psychiatric treatment - prescribed the inter-
ventions for each functional problem. Staff members were
trained to systematically conduct the IRR programme.
Monitoring took place weekly during the course of the
personal intervention plan and was guided by the method
of standardized goal attainment scaling (GAS: score range
1 to 7; 7 = independent (no help needed) [14]. Each dis-
cipline provided a written GAS score, based on functional
progress during the therapy sessions. These scores were
discussed in the multidisciplinary meeting, without the
patients/caregivers, and a consensus GAS score was
determined.
UC consisted of a relatively high level of nursing home
care. This care is provided by a multidisciplinary team.
In this study, UC was provided in the following settings:
at home (n=22; 25.3%), at home with mental healthcare
(out-reaching) or psychogeriatric day care/treatment
(n=14; 15.7%), in an assisted living residence (n=6;
7.2%), and in a nursing home (n=45; 51.8%). The multi-
disciplinary UC staff consisted of a nursing home phys-
ician or social geriatric physician, a psychologist, a
paramedical team (physiotherapist, occupational therap-
ist, speech therapist, welfare worker) and a nursing team
(Registered Nurses, Certified Nurse Assistants and/or
100.0%
48.7%
79.5% Psychogeriatrician
57.7% Nurses Therapists *) Psychologist
94.9% Nurses
Support 66.6% Nurses Therapists *) Welfare worker
38.5%
47.4% Nurses Occup therapist Welfare worker
41.0%
Discharge
Diagnostic assessment
Treatment components Disciplines
Phase 1 (Diagnostic phase)
Multidisciplinary
Phase 2 (Treatment phase)
Interpersonal therapy Psychologist
Counseling Psychologist
Cognitive-behavioural therapy
One of the following:
Behavioural therapy Therapists *)
Family therapy Psychologist
Phase 3 (Discharge phase)
Rehabilitation
Support (discharge) Social worker
physiotherapist
occupational therapist
*) for each patient, two or three of the following
  therapists are involved in the psychotherapeutic
  programme:
psycho-motor therapist
music therapist
creative therapist
Figure 1 Flowchart of IRR treatment programme, distinguished by three phases.
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core multidisciplinary teams, each working from a differ-
ent, mostly emotion-oriented, theoretical framework.
Assessments
We used two sets of instruments, one for the patient
and caregiver, and one for the economic aspects. Mul-
tiple psychiatric Symptoms (MPS) of the patient was
assessed by the Neuropsychiatric Inventory (NPI 12 item
version: ‘NPI-sum-severity’ : 0 to 144; 0 = no severity
symptoms at all), administered to the caregiver [15]. We
chose the caregiver NPI, because the caregivers formed
a stationary group from the moment of inclusion in thestudy until the end of the treatment and the six-month
follow-up. Furthermore, they generally provide a better
reflection of the actual needs, thoughts and feelings of
dementia patients than the relatively discontinuous nurs-
ing teams can provide [16]. General burden of the care-
giver was assessed using the Caregiver Burden (CB: 0 to
100; 0=optimal) [17], and competence with the Caregiver
Competence List (CCL: 28 to 112; 112=optimal) [4,18].
MMSE was used to measure patient memory (0 to 30;
30=normal) [19], and self-care was assessed using the
Barthel Index (BI) (0 to 20; 20=normal) [20]. To assess
the risk for being placed in a nursing home we used the
Global Deterioration Scale (GDS: 1–7; 1 is normal)
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International Classification of Diseases (ICD-10). The
DSM IV disorders (axes I and II) were classified by a
research psychiatrist. The following demographic data
were collected: gender, age, marital status, family rela-
tion, residence, education level, income level and job
employment.
For the economic evaluation, i.e. cost utility analysis,
we assessed quality of life with EuroQol Health ques-
tionnaire (EQ5D) (−0.59 to 1.0; 1.0=optimal), adminis-
tered to the patient [22]. The EQ5D is a validated tool
for measuring general health–related quality of life.
EQ5D consists of five items (mobility, self-care, usual ac-
tivities, pain/discomfort and anxiety/depression), each
having the rating options ‘no problems’, ‘some problems’
and ‘extreme problems’. The health descriptions can be
linked directly to empirical valuations of the general
public, which allows utilities to be computed [23].
Costs were estimated by multiplying the use of health
care by their corresponding unit prices. The number of
days admitted to the nursing home was collected directly
from the participating centres. The questionnaire
Trimbos iMTA for Costs associated with Psychiatric ill-
ness (TiC-P), which asks about the number of health
care contacts over the previous four weeks, was applied
to collect data on all other use of health care from the
patients. We used TiC-P to collect data on direct med-
ical costs [24]. Unit prices of the interventions for the
year 2004 were estimated based on information provided
by the financial department of Argos Zorggroep. There-
fore, data on the direct (e.g. medical staff, nursing staff )
and indirect costs (e.g. overhead, housing) of 2004 was
used to calculate the unit costs per day for IRR and UC,
respectively. All other health care utilisation was valued
using their corresponding unit prices based on the
Dutch manual for costing studies in Economic Evalua-
tions [25]. Unit prices of health care services for 2004
were adjusted to 2005 prices using the consumer price
index (www.cbs.nl). So, all relevant health care costs
were included.
The patient mean utility scores were estimated by ap-
plying the area-under-the curve method (AUC) [25].
The data scores of patients who died were valued zero if
the patient died in the first 4 weeks of a measurement
period or in any of the consecutive measurement pe-
riods. If a patient died in the last 4 weeks of a measure-
ment period we valued the data scores as missing, or the
available scores of the measurement period in which the
person died, and zero in the consecutive periods.
Economic evaluation
The cost-utility was evaluated by relating the difference
in total direct medical costs per patient to the difference
in terms of Quality Adjusted Life Years gained (QALY),which yielded a cost per QALY estimate. In addition, to
estimate the cost effectiveness of IRR versus UC, we
determined the Incremental Cost-Effectiveness Ratio
(ICER) by comparing the two conditions on mean differ-
ences in total medical costs divided by mean differences
in effects on NPI, CB and CCL, respectively [26]. The
estimated participation interval of dropouts (time in
days participating in the study) was determined using a
Cox-regression analysis. All significance testing was fixed
at P<0.05 (two-tailed). The data were analyzed according
to the intention to treat (ITT)-principle. The statistical
analyses were performed with the software programmes
SPSS, version 21, and SAS, version 9.2.Results
Characteristics of the study sample
Of the 336 eligible individuals, 168 (50%) consented to
participate in the RCT (Figure 2). The non-participants
did not differ significantly from the participants on the
inclusion criteria. The difference between the two study
groups in number of dropouts was insignificant. More-
over, the dropouts did not differ significantly with regard
to any baseline assessment or on length of time partici-
pating in the programme (Cox regression analysis: HR
1.21; P<0.54).
The IRR group and UC group differed significantly
only on somatic co-morbidity (Table 1). All statistical
analyses were adjusted for somatic co-morbidity. A
mean GDS-score of 4.2 (SD 0.8) suggested that the study
sample consisted of psychogeriatric patients with mild
cognitive impairment or dementia who were at high risk
for admission to a nursing home [27]. The mean sum-
severity of NPI-symptoms of the patient (IRR 35.90 and
UC 29.68) was relatively high (Table 2). Kaplan-Meier
analysis showed that the length of stay in a nursing
home after the end of treatment did not differ signifi-
cantly between the two groups: IRR mean (147.04 days,
95% CI: 123.77 to 170.31), and UC mean (151.82 days;
95% CI: 130.11 to 173.37; p<0.62) (Table 3).Economic evaluation
At baseline, TiC-P and EQ5D data were available for
96% (n=161), and at 40 weeks follow-up for 38% (n=63)
of the participants. Table 3 shows that the mean nursing
home costs per patient (including the costs of IRR) were
non-significantly higher in IRR than in UC. However,
the costs of home care and day care were significantly
lower in IRR. The mean costs in IRR were non-
significantly (10.5%) higher (€ 3,205; 95% CI: 374.20 to
10153.20) than those in UC. This implies € 36 extra per
IRR-treatment day (in total: average 90 days treatment
duration). Moreover, the number of QALYs of the pa-
tients was non-significantly (0.01) higher in IRR (95%
  n=168
  n=152
  n=9
  n=7
Time1: Time 1: 
available: n=78 available: n=83 1)
death: n=2 death: n=4
refusal: n=1 refusal: n=0
loss: n=0 loss: n=0
 n=3 n=4
5%
available: n=69 available: n=77 2)
death: n=10 death: n=9
refusal: n=1 refusal: n=0
loss: n=1 loss: n=1
n=12 n=10
15% 12%
available: n=54 available: n=64 3)
death: n=24 death: n=23
refusal: n=2 refusal: n=0
loss: n=1 loss: n=0
n=27 n=23
33% 26%
Eligible patients (n=336)
Not randomized
Refusal of referral/treatment 
Refusal of participation 
Did not receive standard Did not receive experimental
intervention as allocated       n=1 intervention as allocated       n=1
Reasons unknown 
IRR UC
Intervention as allocated (n=81) Intervention as allocated (n=87)
Time 2: Time 2: 
total dropout: total dropout:
total dropout: total dropout:
4%
1) Fisher's Exact test for dropout * condition  p 1,00 (two-tailed)
2) Fisher's Exact test for dropout * condition  p 0,494 (two-tailed)
3) Fisher's Exact test for dropout * condition  p 0,138 (two-tailed)
Time 3: Time 3: 
total dropout: total dropout:
Randomization
n=168
Figure 2 Flowchart study sample, distinguished by treatment condition.
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per QALY.
Table 4 presents the cost-effectiveness of IRR in
ICERs. IRR was significantly more effective on the pri-
mary outcome variable NPI-sum-severity of the patient
as well as on the secondary outcome variables caregiver
burden and caregiver competence. The effects of IRR
were about twice as large as of those of UC. For NPI-
sum-severity, the ICER equalled to about € 320.–, imply-
ing that the cost of one surplus point improvement inIRR was € 320 (mean difference IRR-UC=10 points).
The least expensive was improvement on general burden
of the caregiver, ICER € 130 (mean difference 25 points).
The ICER of competence of the caregiver was € 540
(mean difference 6 points).
The cost-effectiveness acceptability curve (CEAC) il-
lustrates the uncertainty surrounding the estimate of
cost- effectiveness [28-32]. CEACs are intended to repre-
sent the uncertainty concerning the cost-effectiveness of
a health-care intervention in the context of decision
Table 1 General details of participants, distinguished by
intervention
IRR UC
n=81 n=87 p-value
Patient characteristics
Gender (females) 66.7% 62.1% 0.63 1)
Age (in years), mean (SD) 79.8 (6.1) 81.5 (7.1) 0.10 2)
Marital status: alone 77.8% 80.5% 0.71 1)
Educational level: low 67.5% 68.7% 0.90 1)
Domicile: at home 76.5% 66.7% 0.17 1)
Primary caregiver: spouse 17.3% 13.8% 0.33 1)
DSM-IV dementia, (axis-I),
count (%):
Dementia of the Alzheimer’s type 18.5% 17.2% 0.84 1)
Vascular dementia 23.5% 25.3% 0.86
Dementia due to other conditions 16.0% 19.5% 0.69
Amnestic/cognitive disorders 32.1% 31.0% 1.00
Other 6.2% 2.3% 0.26
DSM-IV personality disorders
(axis-II), count (%)
16.0% 9.2% 0.24
MMSE 20.0(4.5) 20.9(3.8) 0.42 2)
Barthel index 15.4(3.8) 14.7(3.6) 0.25
GDS-deterioration, mean (SD) 4.2 (0.7) 4.3 (0.9) 0.62
Somatic co-morbidity (ICD-10),
mean (SD)
5.6 (2.6) 4.5 (2.4) 0.01 2)
Nursing home days (LOS),
mean (SD)
147.0
(107.0)
151.8
(103.9)
0.62 2)
Caregiver characteristics
Gender (females) 70.5% 61.7% 0.32 1)
Age (in years), mean (SD) 58.6
(11.9)
58.9
(12.0)
0.86 2)
Marital status: living together 91.4% 94.8% 0.52 1)
Educational level: low 4.3% 2.6% 0.39 1)
1)Fisher’s exact test (two tailed).
2)t-Test (two tailed).
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confidence intervals around ICERs [28]. Nowadays, use
of CEACs has become widespread amongst others in the
field of medicine [33-37].
The CEAC is based on the joint density of incremental
costs (ΔC) and incremental effects (ΔE) for the interven-
tion of interest (IRR), and represents the proportion of
the density where the intervention is cost-effective for a
range of values of λ. In our study, the CEAC is estimated
by parametric bootstrapping of the distribution
[28,29,31]. The CEAC is determined as the proportion
of the (ΔC/ ΔE) points where the intervention is consid-
ered cost-effective [29].
Figure 3 shows the mean differences in costs and the
mean difference in the outcome measure QALYs using1000 bootstrap replicates of the trial data (differences
based on IRR minus UC). This illustrates the uncertainty
surrounding the estimates of expected cost-effectiveness
(in €) between IRR and UC. In 10.6% of the simulations,
IRR is both less effective and more costly, and hence un-
acceptable. Conversely, in 9.8% of the simulations IRR is
both more effective and less costly and hence acceptable,
regardless of societies willingness to pay (threshold) for
a QALY. For all other simulated outcomes, the accept-
ability depends on the threshold cost-effectiveness ratio
(ICER). Figure 4 shows for a range of threshold ICERs
the proportion of simulated outcomes that is acceptable,
or in other words, the probability that IRR is cost-
effective compared to UC.
Figure 5 shows the mean differences in costs and the
mean difference in the outcome measure NPI-severity
using 1000 bootstrap replicates of the trial data (differ-
ences based on IRR minus UC). This illustrates the un-
certainty surrounding the estimates of expected cost-
effectiveness (in €) between IRR and UC. In 4.2% of the
simulations, IRR is both less effective and more costly,
and hence unacceptable. Conversely, in 0.0% of the sim-
ulations IRR is both more effective and less costly and
hence acceptable, regardless of societies willingness to
pay (threshold) for improvement on NPI-severity. For all
other simulated outcomes, the acceptability depends on
a to be determined threshold cost-effectiveness ratio
(ICER). Figure 6 shows for a range of threshold ICERs
the proportion of simulated NPI-severity outcomes that
is acceptable, or in other words, the probability that IRR
is cost-effective compared to UC.
Discussion
The objective of this study was an economic evaluation
of an Integrative Reactivation and Rehabilitation (IRR-)
programme. IRR was focused on psychogeriatric patients
who were at high risk for admission to a nursing home.
We estimated the cost-utility (QALYs) and cost-
effectiveness (ICERs) of IRR by comparing IRR to usual
multidisciplinary nursing home care (UC). The cost-
utility analysis (CUA) shows that the amount of QALYs
for psychogeriatric patients was almost equal between
IRR and UC, while the costs were 10.5% lower in UC.
Overall, the costs per QALY for IRR were far higher than
€ 30,000 per QALY (€ 275,000 per QALY) which the
Dutch National Council for public health and health
care assumes to be the threshold for cost-effectiveness
of sustainable and meaningful care (2006) [38]. To test
the sensitivity of the results for missing data we also ap-
plied the multiple imputation methodology, a technique
commonly applied in economic evaluations [39,40].
Using multiple imputation, total medical costs in IRR
were significantly higher than in UC (€ 4.572,–; 95% Cl:
364.24 to 8797.76) and the number of QALYs was non-
Table 2 Level of outcome across time (T1 - T3) distinguished by intervention
T1 (baseline measurement) T3 (six months follow-up)
IRR UC IRR UC
Range High score n Mean SD n Mean SD Mean 95% CI n Mean n Mean
= (+/−) *) diff.
Psychiatric function disorders patient
(by caregiver)
NPI-sum-severity 0 to 144 (−) 72 35.90 21.84 76 29.68 20.12 −6.22 −13.05 0.62 49 15.84 51 18.61
Caregiver burden
Caregiver burden (CB) 0 to 100 (−) 72 52.47 25.65 77 46.69 27.66 −5.79 −14.42 2.85 42 28.81 50 44.90
Competence (CCL) 28 to 112 (+) 72 84.62 14.24 77 86.58 14.46 1.96 −2.69 6.6 49 96.35 50 91.78
Quality of life patient
EQ5D −0.59 to 1.00 (+) 77 0.54 0.34 80 0.58 0.29 0.04 −0.06 0.14 45 0.62 62 0.55
*) + = high score is beneficial, - = high score is unfavourable.
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Table 3 Mean direct medical costs (€) and mean QALY after 40 weeks for IRR and care as usual
Complete case analysis (CC)
Mean
Mean IRR1) 95% CI Mean UC2) 95% CI UC-IRR 95% CI
Week 40
Home care 21.05 0.00 65.01 2895.01 1214.53 4825.43 2873.96 1182.33 4807.01
Day care 0.00 0.00 0.00 2279.18 730.57 4328.72 2279.18 730.57 4328.72
Hospital 964.74 259.62 1873.95 420.34 0.00 913.12 −544.40 −1768.63 422.81
Nursing home (incl. IRR) 27675.61 22546.21 32545.24 20123.51 14258.25 26691.78 −7552.10 −15927.53 −8971.61
Assisted living residence 4902.63 2711.53 7396.54 4033.14 1643.42 6457.91 −869.49 −4335.40 2538.42
Other care 149.16 74.48 243.83 757.05 259.28 1338.68 607.89 91.75 1207.87
QALY 0.43 0.36 0.51 0.42 0.36 0.48 0.013 3 −0.09 0.11
Direct medical costs 33713.00 27961.18 39220.66 30508.00 25696.53 35270.19 −3204.95 −10326.22 4812.52
1)Integrative reactivation and rehabilitation.
2)Usual care.
3)Costs per Qaly € 276,289.70.
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http://www.biomedcentral.com/1472-6963/13/370significantly lower (0.02; 95% CI: -0.09 to 0.05). So, this
analysis supported the conclusion that IRR apparently is
not cost-effective in terms of QALYs. Moreover, CEAC
of QALYs suggests that, when the costs per patient
around € 60,000 is acceptable, then the probability is
0.50 that the treatment (i.c. IRR) is considered cost-
effective compared to UC.
In contrast, at six-month follow-up, the cost-
effectiveness analysis in terms of ICERs showed signifi-
cant surplus improvement of patients (up to 34%) and
caregivers (up to 50%) in IRR. Surplus improvement of
the patient on severity of multiple psychiatric symptoms
was about € 320 per point. For the caregivers, the sur-
plus improvement on general burden was about € 130
per point and on competence € 540. These are clinically
relevant results because MPS of patients and caregiver
burden are the two phenomena experienced as most
problematic in dementia care [41]. CEAC of MPS sug-
gests that, when the costs per patient around € 600 is ac-
ceptable, then the probability is 0.50 that the treatment
(i.c. IRR) is considered cost-effective compared to UC.
However, the cost-effectiveness results are not easily
compared to cost-effectiveness of other health care in-
terventions, because there is no reference value of costs
per effect unit for these clinical outcomes. Hence, thisTable 4 Cost-effectiveness after 40 weeks; distinguished by In
High score Costs Eff
=(+/−) *) Costs IRR Costs UC
WEEK 40
NPI-sum-severity (−) 33713.19 30508.23 2
Caregiver burden (CB) (−) 33713.19 30508.23 2
Caregiver competence (CCL) (+) 33713.19 30508.23 1
*) + = high score is beneficial, - = high score is unfavourable.type of information is of less value in health care policy
decision making than costs per QALY.
The difference in results between QALYs and ICERs is
remarkable. In terms of mean differences, the cost-
effectiveness on clinically relevant outcomes, i.e. severity
of psychiatric symptoms in psychogeriatric patients,
caregiver burden and competence was relatively large
and in favour of IRR [42,43]. In contrast, the mean dif-
ference between the IRR and UC on the EQ5D was
minor (0.04; 95% CI: -0.06 to 0.14), with only relatively
small percentages of clinically relevant (≥ 0.5 SD) im-
proved patients (IRR 24% vs. UC 15%) [12,13]. This
means that the EQ5D proved to be relatively unrespon-
sive to change. This corresponds to the findings of Bal-
lard et al. [44], who showed that clinically relevant
improvement on Behavourial and Psychological Symp-
toms of Dementia (BPSD) had only small effects on
general quality of life measurements. Completion of the
EQ5D by proxy (i.e. the caregiver) may enhance the
correlation between EQ5D and BPSD [35]. All in all, this
does not facilitate comparison of the effects of interven-
tions in cost-utility studies in psychogeriatrics. Further
research is urgently needed [45-48].
One of the strengths of this study was that it was
based on a relatively large sample size of patients.tervention; ICER-approach
ects Costs Effects ICER
IRR UC IRR-UC p-value IRR-UC p-value Costs/effects
1.78 11.86 3204.95 0.37 9.92 0.04 323.08
4.76 0.00 3204.95 0.37 24.76 0.00 129.44
0.35 4.42 3204.95 0.37 5.93 0.01 540.46
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Figure 3 Cost-effectiveness plane of incremental costs and incremental effects for QALYs.
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http://www.biomedcentral.com/1472-6963/13/370Furthermore, it was possible to estimate the benefit of
full participation as the relatively high percentage of
dropouts did not differ significantly on the observed
variables. The majority of dropouts could be ascribed to
death, which was not significantly different between IRR
and UC. The phenomenon of high dropout percentages
is well known in geriatric research [5-7]. It basically
reflects the vulnerability of the psychogeriatric patients
suffering from MPS.
How can the results be interpreted within the context
of the literature? They confirm that psychotherapeutic
treatment, based on person-oriented and problem-
solving principles, is effective in psychogeriatric patients
[46,48]. Moreover, the relative unresponsiveness of the
patient’s EQ5D compared to the positive changes on the
severity of MPS is in line with the results reported in
literature [44-48]. Furthermore, as far as we know, our0
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Figure 4 Cost-effectiveness acceptability curve for QALYs, ICER-approRCT-study was one of the first comprehensive studies in
a nursing home setting with a relative large sample size
to address integrative psychotherapeutic treatment of
psychogeriatric patients and their caregivers [7,9].
However, the study had some weaknesses. First of all,
RCT was not blinded. In a clinical study like this,
blinding is not feasible. As the research staff had to visit
the patients and caregivers personally, they knew the
intervention history of the patients. Although we trained
the research staff to administer the assessment instru-
ments, this was no guarantee that information bias was
precluded. Whether bias emerged in favour of IRR is dif-
ficult to demonstrate. As the assessments at baseline
showed only minor differences between IRR and UC,
except for somatic co-morbidity, the information bias at
baseline seems to be limited. Another weakness was that
only direct medical costs of patients were available; any60000 80000 100000
 ICER
ach.
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Figure 5 Cost-effectiveness plane of incremental costs and incremental effects for NPI-severity.
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http://www.biomedcentral.com/1472-6963/13/370other costs, specifically costs related to informal care at
home, had to be excluded. This may have led to an
underestimation of costs at home, especially in UC. A
third limitation was the absence of (medical) cost-data
for the caregiver. Especially, the significantly large bene-
ficial effects of IRR on carer burden and competence
may have lowered their medical consumption. This
means that the results of the economic evaluation sug-
gest a probable underestimation of (cost-)effectiveness of
IRR. Furthermore, the study ended at 40 weeks.
Regarding generalization of the findings of this RCT, it
is important to keep in mind that 50% of the eligible pa-
tients refused to participate. A relatively large proportion
of these patients lived with a spouse. However, post-hoc
prognostic analysis showed that living together did not
have any prognostic quality with respect to improvement
on the primary outcome variable. In IRR the beneficial
long-term effects on the patient and the caregiver con-
firm those mentioned in the literature [46,48]. It is0
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Figure 6 Cost-effectiveness acceptability curve for NPI-severity, ICER-expected that by identifying the less effective therapeutic
components and subsequently making them more effect-
ive or leaving them out, the cost-effectiveness of IRR
may increase. Identification of and screening for those
psychogeriatric patients and their caregivers with a rela-
tively high likelihood of improving, presents another
opportunity to increase the cost-effectiveness of IRR.
Conclusion
In terms of QALYs, IRR did not seem to be cost-
effective as compared to UC. However, at six-month
follow-up, fully participating patients and caregivers in
IRR improved significantly more on the clinically rele-
vant parameters, i.e. severity of psychiatric symptoms
(up to 34%) as well as on caregiver burden (up to 50%).
Furthermore, the surplus effect on the competence of
caregivers was substantial. The incremental costs-
effectiveness ratios varied from € 130 to € 540 per add-
itional point of improvement, on the multiple psychiatric3000 4000 5000
atio
approach.
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http://www.biomedcentral.com/1472-6963/13/370symptoms (MPS) of the patient and caregiver burden
and competence respectively. The total medical costs
were 10.5% higher in IRR. The large discrepancies be-
tween IRR and UC on QALYs and ICERs demand fur-
ther research regarding EQ5D validation in intervention
studies with psychogeriatric patients. Considering all
available evidence, the surplus costs of IRR may be con-
sidered acceptable when taking into account the benefi-
cial effects on the high societal costs of suffering from
multiple psychiatric symptoms of psychogeriatric pa-
tients and high burden of caregivers. To optimize the
cost-utility and cost-effectiveness of IRR, the develop-
ment of a tool to identify suitable psychogeriatric pa-
tients and caregivers for IRR is of key clinical and
economic importance. Such a tool would contribute to
the optimization of medical decision making based on
an economical evaluation. Future studies that include
caregiver costs have to be performed to strengthen the
evidence, preferably RCTs.
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